← Back to Search

CHaRRM Counseling for Opioid Use Disorder (CHaRRM-CN Trial)

N/A

Recruiting

Led By Ashley Lincoln, MSW

Research Sponsored by Washington State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, month 1, month 3, month 6

Awards & highlights

CHaRRM-CN Trial Summary

This trial tests if a program aiming to improve retention in MAT, reduce substance-related harm and increase cultural connectedness is effective.

Who is the study for?

This trial is for adults over 18 who are new to the Cherokee Nation Health Services Medication-assisted Treatment (MAT) Program or returning after a six-month break. They must be able to understand and agree to the study's terms. People can't join if they're unable to consent or pose a risk to others' safety.Check my eligibility

What is being tested?

The trial tests CHaRRM-CN, a program aiming to improve patient retention in MAT, reduce opioid-related harm, and boost cultural ties within the Cherokee Nation. Participants will either receive this new counseling approach or standard treatment for comparison.See study design

What are the potential side effects?

Since this trial focuses on counseling methods rather than medication, traditional side effects like those seen with drugs aren't expected. However, participants may experience emotional discomfort discussing substance use.

CHaRRM-CN Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, month 1, month 3, month 6

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, month 1, month 3, month 6

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 1, month 3, month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

MAT retention

Secondary outcome measures

ED visits

Illicit Opioid Use

Native enculturation

+2 more

Other outcome measures

Health-related quality of life (HR-QoL)

CHaRRM-CN Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: CHaRRM-CNExperimental Treatment1 Intervention

The CHaRRM-CN condition comprises changes and additions to TAU codesigned with a community advisory board and taking into account suggestions from MAT patients and community members impacted by OUD with the goal of improving MAT retention in culturally aligned and community-driven ways.

Group II: Treatment as Usual (TAU)Active Control1 Intervention

The TAU condition will entail the current CNHS MAT program for OUD.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington State UniversityLead Sponsor

101 Previous Clinical Trials

56,524 Total Patients Enrolled

University of WashingtonOTHER

1,741 Previous Clinical Trials

1,847,576 Total Patients Enrolled

Cherokee Nation Health ServicesUNKNOWN

1 Previous Clinical Trials

200 Total Patients Enrolled

Media Library

CHaRRM-CN Clinical Trial Eligibility Overview. Trial Name: NCT05733442 — N/A

Opioid Use Disorder Research Study Groups: Treatment as Usual (TAU), CHaRRM-CN

Opioid Use Disorder Clinical Trial 2023: CHaRRM-CN Highlights & Side Effects. Trial Name: NCT05733442 — N/A

CHaRRM-CN 2023 Treatment Timeline for Medical Study. Trial Name: NCT05733442 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals still able to join this clinical experiment?

"Affirmative. Clinicaltrials.gov records demonstrate that this research project, which was first published on January 17th 2023, is currently enrolling volunteers. Approximately 160 individuals are sought to participate in the trial at a single location."

Answered by AI

What is the current enrollment of participants in this clinical investigation?

"Affirmative. According to clinicaltrials.gov, the recruitment phase of this medical experiment began on January 17th 2023 and concluded February 15th 2023. 160 patients are required between 1 facility for its completion."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

Lonnie Nelson 2023. "Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05733442.